Adage Capital Partners Gp, L.L.C. Aligos Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $51 Billion
- Q1 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,464,505 shares of ALGS stock, worth $985,802. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,464,505Holding current value
$985,802% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding ALGS
# of Institutions
53Shares Held
46.2MCall Options Held
6.11MPut Options Held
200-
Armistice Capital, LLC New York, NY6.89MShares$2.76 Million0.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$2.56 Million0.18% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$2.44 Million0.2% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$1.42 Million0.46% of portfolio
-
Altitude Crest Partners Inc. Stamford, CT2.84MShares$1.14 Million1.19% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $15.9M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...